Conclusions/Relevance: Given the remaining recurrence risk even with these interventions and with the ongoing development of new strategies for HR + disease, patients with high-risk EBC should be encouraged to participate in clinical trials, such as trials of immunotherapy, novel oral estrogen receptor alpha (ERα)-targeting agents,...

Conclusion: These results suggest that abemaciclib is effective, as monotherapy and in combination, for patients with heavily pretreated mBC, consistent with clinical trial results.

Conclusions/Relevance: These considerations highlight the need for a proper clinical staging on locoregional lymph nodes at the diagnosis of disease and the importance of looking for cytological confirmation of all suspect nodes. All these additional criteria shall be stressed and spread to avoid missing any patient that could benefit from an...

Conclusions/Relevance: The selected two compounds are small molecules in the appropriate druglikeness range. The results observed in molecular docking and molecular dynamics simulations were most promising for two compounds, suggesting their potent inhibitory effect against CDK6. We propose that these candidate compounds can undergo in vitro...

Conclusions/Relevance: Advances in the design of antibody-drug conjugates have led to the development of new generation drugs with enhanced properties, such as trastuzumab deruxtecan and trastuzumab duocarmazine, which are significantly changing the paradigm in the treatment of HER2-positive metastatic breast cancer.